|
covid-19 |
57 |
|
chinese |
30 |
|
children |
28 |
|
sars-cov-2 |
24 |
|
epidemiology |
15 |
|
healthcare workers |
15 |
|
hospital policies |
15 |
|
perceived stress |
15 |
|
psychological wellbeing |
15 |
|
child psychosocial problems |
14 |
|
complications |
14 |
|
coronavirus |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
home confinement |
14 |
|
school closure |
14 |
|
covid-19 vaccines |
12 |
|
cytokines |
12 |
|
immunoglobulin |
12 |
|
innate immunity |
12 |
|
lymphocyte subsets |
12 |
|
sars |
12 |
|
tuberculosis |
12 |
|
false positive |
11 |
|
kawasaki disease |
11 |
|
paediatrics |
11 |
|
public health |
11 |
|
serology |
11 |
|
statistics & research methods |
11 |
|
all-cause pneumonia |
10 |
|
herd immunity |
10 |
|
interrupted time series analysis |
10 |
|
pasc |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
age-stratified |
9 |
|
asia |
9 |
|
pediatrics |
9 |
|
pharmacovigilance |
9 |
|
travel history |
9 |
|
vaccine safety |
9 |
|
abdominal pain |
8 |
|
diarrhoea |
8 |
|
drug regulatory |
8 |
|
health equity |
8 |
|
inactivated vaccine |
8 |
|
mrna vaccine |
8 |
|
orphan drug policy |
8 |
|
paediatric gastroenterology |
8 |
|
pediatric population |
8 |
|
rare diseases |
8 |
|
treatment access |
8 |
|
vaccine effectiveness |
8 |
|
blood pressure |
7 |
|
cardiovascular disease |
7 |
|
diabetes mellitus |
7 |
|
mortality |
7 |
|
visit‐to‐visit variability |
7 |
|
adverse drug reactions |
6 |
|
antimicrobial stewardship |
6 |
|
cervical screening |
6 |
|
hong kong |
6 |
|
hpv vaccination |
6 |
|
prescribing |
6 |
|
respiratory tract infections |
6 |
|
sexual behaviour |
6 |
|
cardiovascular disease risk |
5 |
|
pharmacoepidemiology |
5 |
|
treatment outcome |
5 |
|
type 2 diabetes mellitus |
5 |
|
young age of onset |
5 |
|
adhd |
4 |
|
antimicrobials |
4 |
|
atomoxetine |
4 |
|
attention deficit hyperactivity disorder |
4 |
|
database |
4 |
|
meta-analysis |
4 |
|
methylphenidate |
4 |
|
prevalence |
4 |
|
retinal detachment |
4 |
|
rheumatoid arthritis |
4 |
|
sudden death |
4 |
|
taiwan |
4 |
|
tofacitinib |
4 |
|
toxic epidermal necrolysis (ten) |
4 |
|
antipsychotic |
3 |
|
china |
3 |
|
elderly |
3 |
|
lorcaserin |
3 |
|
meta‐analysis |
3 |
|
methodology |
3 |
|
micronutrients |
3 |
|
observational study |
3 |
|
pharmacy and pharmacology |
3 |
|
pregnancy |
3 |
|
prescribing trend |
3 |
|
retina |
3 |
|
weight loss |
3 |
|
adolescent |
2 |
|
attention deficit disorder with hyperactivity |
2 |
|
child |
2 |
|
epilepsy |
2 |
|
fluoroquinolones |
2 |
|
humans |
2 |
|
retina - diseases |
2 |
